This in cis binding sequesters B7.1, but treatment with anti-PD-L1 antibodies prevents B7.1 sequestration, allowing DCs in the tumor microenvironment to exert their T-cell priming effects [64]. This evidence concerns the gene CD80 and neoplasm.